Date: Wednesday 25th November 2020
Time: 14:00 - 15:00 GMT
Speakers: Graham Healey (Oncimmune) and Dea Putri (Janssen)
Who is this event intended for? Anybody involved in the development and deployment of biomarkers in pharmaceutical or diagnostic areas.
What is the benefit of attending? To gain an appreciation of the range of issues at the non-clinical end.
You can now register for this event. Registration will close at 12:00 on 24th November 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
The deployment of biomarkers in drug development and diagnostics has many challenges ranging from analytical validation, in vivo study design, to the translation to human utility and financial considerations. In this Webinar focus will be given to safety biomarkers. Statistical issues in data science that nonclinical statisticians might encounter along the way will be discussed.
|
Speaker: Graham Healey Biography: Graham has 40 years experience in supporting R&D in the pharmaceutical and diagnostics industries, particularly in the areas of discovery, toxicology, assay validation and clinical trials. After graduating in Zoology from Imperial College, he then converted to full-time statistics via the MSc Biometry course at Reading. After a year lecturing at Bunda Agricultural College deep in the Malawian bush, he joined the biotech division of G.D.Searle UK, working on interferon and aspartame. Next came six years at Searle's R&D site in Belgium followed by 16 years as Head of Statistics at HLS in UK, working in a vast array of preclinical, toxicology and clinical areas. He is currently Chief Statistician at Oncimmune Ltd, involved in all stages of the commercialisation of blood tests for the early detection of cancer, from laboratory bench to doctor’s surgery. In his spare time his main passions are classical music and insects. |
|
Speaker: Dea Putri Biography: Right after graduating from her master study in biostatistics at Hasselt University, Belgium, Dea directly joined the discovery statistics at Janssen Pharmaceutica in 2015 as biostatistician. In this role, Dea closely collaborates with other statisticians as well as scientist from different therapeutic area to provide solutions from day to day business needs to a more specific cases which need tailor-made analysis. Dea is building her expertise in high dimensional data integration on pre-clinical as well as clinical studies. At the moment, Dea is also finishing her doctoral school at Hasselt University under supervision of Prof. Ziv Shkedy and Prof. Luc Bijnens with research topic related to statistical method development for the design and statistical analysis of high dimensional data integration. |
